In AML, the groups that were not treated with CTx or exhibited an absence of CD117 showed unfavourable 30-day survival, with hazard ratios of 8.47 (3.584–18.076) and 5.68 (2.638–12.230), respectively (P < 0.001, both). The gene discussed is KIT; the disease is acute myeloid leukemia.